Prevent osteoporosis by understanding low bone density, risk factors, prevention strategies, and treatment options for ...

Alendronate has been shown to increase bone mineral density (BMD) and decrease fracture risk in postmenopausal women with osteoporosis, but the need for long-term treatment is unclear, especially ...

The FDA has approved two new biosimilars of denosumab for all indications of the reference medications Prolia and Xgeva, ...

US FDA approves Celltrion’s Stoboclo and Osenvelt biosimilars referencing Prolia and Xgeva: Jersey City, New Jersey Wednesday, March 5, 2025, 18:00 Hrs [IST] Celltrion, a leadin ...

Stoboclo, a biosimilar to Prolia, is indicated for postmenopausal women and men at high risk of fracture, while Osenvelt, a ...

In accordance with a settlement agreement with Amgen Inc., STOBOCLO and OSENVELT are expected to be available in the U.S. in June 2025.

The FDA has approved Stoboclo (denosumab-bmwo), a biosimilar to Prolia (denosumab), and Osenvelt (denosumab-bmwo), a biosimilar to Xgeva (denosumab).

The FDA approved Stoboclo and Osenvelt, denosumab biosimilars that could offer more affordable treatment options for ...

Romosozumab plus alendronate vs alendronate alone was associated with improved lumbar spine BMD in postmenopausal women with T2D.

The Philippine Academy of Rehabilitation Medicine (PARM) commemorated its 50th anniversary during its 35th Annual PARM Convention, held alongside the 9th ASEAN Rehabilitation Medicine Association ...